BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status
6.4.2022 16:00:00 EEST | Business Wire | Press release
BostonGene today announced the completion of the $150 million Series B funding. NEC Corporation (NEC; TSE: 6701) led the financing with participation from Impact Investment Capital and Japan Industrial Partners. The capital will be used to scale BostonGene’s growth, including continued innovation, clinical and research partnerships, and international expansion. Further, leveraging NEC’s robust infrastructure, BostonGene and NEC intend to form a joint venture to bring lifesaving solutions to patients in Japan and other Asian countries.
“Many academic and community oncologists across the United States have already adopted BostonGene’s Molecular Portrait Test to improve their patients’ quality of care,” said Takayuki Morita, President and CEO at NEC Corporation. “NEC recently launched a healthcare and life science business unit that utilizes AI and other digital technologies as a key initiative within our 2025 Mid-term Management Plan. We are thrilled to expand on our strategic partnership with BostonGene to advance how physicians treat their patients and dramatically improve clinical outcomes in the U.S., Japan, and the rest of the world.”
“BostonGene has a unique opportunity to build a very large economic value that creates an even larger social impact. That combination is extremely rare, and I am excited and humbled by it,” said Andrew Feinberg, President, and CEO at BostonGene. “This capital positions us well to execute on our vision to enable personalized treatment of cancer patients based on integrated molecular profiles of the tumor, tumor microenvironment, and host immunity.”
BostonGene’s innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient’s immune system, and the effectiveness of all available approved and investigational treatments. The BostonGene Tumor Portrait™ Tests, a sophisticated analysis of the tumor and tumor microenvironment (TME), reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, and biomarkers of response to diverse therapies, and recommended therapies. BostonGene’s integrated model of tumor genetics, transcriptomics, microenvironment, and tumor composition provides a 360° overview of a patient tumor to give physicians invaluable insights into potential treatment options.
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes to promote a more sustainable world for everyone. For more information, visit NEC at https://www.nec.com.
About Impact Investment Capital
Impact Investment Capital invests in opportunities with the intention to generate a measurable, beneficial social or environmental impact alongside a financial return.
About Japan Industrial Partners, Inc.
Japan Industrial Partners (JIP) is a private equity firm based in Tokyo, Japan. JIP aims to provide funds and solutions to businesses with significant growth opportunities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005384/en/
Contact information
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com
NEC
Joseph Jasper
j-jasper@nec.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom